Opportunity Information: Apply for RFA DK 19 022
The Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) funding opportunity (RFA-DK-19-022) is a National Institutes of Health cooperative agreement (U01; clinical trial optional) designed to build a coordinated, multi-site clinical research network focused on diabetes that appears during an episode of acute pancreatitis or develops afterward. The main scientific emphasis is on type 1 diabetes (T1D), but the program also aims to characterize other diabetes phenotypes that may emerge in this clinical setting. The award supports the creation of up to 10 Clinical Centers (CCs) that will work closely with a separately funded Data Coordinating Center (DCC) to run shared protocols, collect harmonized data and biospecimens, and produce generalizable findings across a diverse patient population.
At the core of the consortium is a prospective, longitudinal observational study following people who experience acute pancreatitis and then develop impaired glucose tolerance or diabetes during the episode or in the months that follow. By tracking participants over time, the consortium is expected to clarify how often diabetes occurs after acute pancreatitis, how it evolves clinically, and how different underlying pancreatitis etiologies relate to diabetes onset and progression. The program is also intended to sort out the "type" of diabetes that develops in these patients, distinguishing T1D and other forms through clinical course, laboratory measures, and mechanistic signals, with the broader goal of improving diagnostic accuracy and anticipating treatment needs earlier.
A major deliverable of the consortium is deeper insight into etiology and pathophysiology, particularly around why a subset of acute pancreatitis patients may develop autoimmune features consistent with T1D. To do that, the Clinical Centers, in partnership with the DCC, will pursue immune profiling and genetic studies and will work to identify biomarkers that predict who is most likely to progress from normal glucose handling to impaired glucose tolerance and then to diabetes, including T1D. The FOA highlights the importance of enrolling a racially, ethnically, and geographically diverse cohort, which is critical both for equity and for ensuring that predictive biomarkers and risk models are valid in real-world populations rather than only in narrowly defined groups.
From a structural standpoint, this is a cooperative agreement, meaning NIH will have substantial involvement beyond standard grant oversight, and the CCs are expected to operate as a true consortium with common governance, shared procedures, and coordinated operations with the DCC. The DCC application is not part of this announcement; it is competed separately under RFA-DK-19-023, and the Clinical Centers funded under this FOA would be expected to integrate seamlessly with the DCC for data management, quality control, statistical support, and cross-site coordination.
The opportunity is offered by the U.S. Department of Health and Human Services through NIH, falls under CFDA 93.847, and supports awards with an upper budget limit listed at $175,000 (award ceiling). NIH anticipated making up to 10 awards for Clinical Centers. Eligible applicants are broad and include many government entities (state, county, city/township, special districts), public and private institutions of higher education, tribal governments and organizations, nonprofits with or without 501(c)(3) status, public housing authorities/Indian housing authorities, for-profit organizations (other than small businesses), and small businesses, with additional eligibility details referenced in the full announcement. Key dates included a creation date of December 2, 2019 and an original closing date of March 13, 2020.Apply for RFA DK 19 022
- The Department of Health and Human Services, National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on Dec 02, 2019.
- Applicants must submit their applications by Mar 13, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $175,000.00 in funding.
- The number of recipients for this funding is limited to 10 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity?
This opportunity is for the Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) under FOA RFA-DK-19-022. It is a National Institutes of Health (NIH) cooperative agreement intended to create a coordinated, multi-site clinical research network focused on diabetes that appears during an episode of acute pancreatitis or develops afterward.
What funding mechanism is being used?
The mechanism is a cooperative agreement (U01), with clinical trial optional. Because it is a cooperative agreement, NIH will have substantial involvement beyond standard grant oversight, and awardees are expected to operate as part of a coordinated consortium.
What is the main scientific focus of the program?
The main scientific emphasis is on type 1 diabetes (T1D) that occurs during or after acute pancreatitis. The program also aims to characterize other diabetes phenotypes that may emerge in this clinical setting.
How many awards does NIH expect to make?
NIH anticipated making up to 10 awards to support up to 10 Clinical Centers (CCs).
What is the award budget limit (ceiling)?
The upper budget limit listed for this opportunity is $175,000 (award ceiling).
Who is the sponsoring agency?
The opportunity is offered by the U.S. Department of Health and Human Services through the National Institutes of Health (NIH).
What is the CFDA number associated with this opportunity?
This opportunity falls under CFDA 93.847.
What are the key dates provided for this opportunity?
The information provided lists a creation date of December 2, 2019 and an original closing date of March 13, 2020.
What are Clinical Centers (CCs) expected to do?
Clinical Centers are expected to work as part of a coordinated consortium to run shared protocols, collect harmonized data and biospecimens, and produce generalizable findings across a diverse patient population. They are also expected to coordinate closely with a separately funded Data Coordinating Center (DCC).
What is the role of the Data Coordinating Center (DCC)?
The DCC will provide data management, quality control, statistical support, and cross-site coordination. Clinical Centers funded under this FOA are expected to integrate seamlessly with the DCC.
Is the DCC application included in this funding announcement?
No. The DCC is competed separately under RFA-DK-19-023. This announcement is specifically for Clinical Centers under RFA-DK-19-022.
What type of study is at the core of the consortium?
The core study is a prospective, longitudinal observational study that follows people who experience acute pancreatitis and then develop impaired glucose tolerance or diabetes during the episode or in the months that follow.
What outcomes or questions is the observational study intended to address?
By tracking participants over time, the consortium is expected to clarify how often diabetes occurs after acute pancreatitis, how it evolves clinically, and how different underlying acute pancreatitis etiologies relate to diabetes onset and progression.
How will the consortium distinguish type 1 diabetes from other forms of diabetes in this setting?
The consortium aims to sort out the "type" of diabetes that develops by using clinical course, laboratory measures, and mechanistic signals, with the goal of improving diagnostic accuracy and anticipating treatment needs earlier.
What is a major deliverable or scientific output expected from the consortium?
A major deliverable is deeper insight into etiology and pathophysiology, including understanding why a subset of acute pancreatitis patients may develop autoimmune features consistent with type 1 diabetes.
What kinds of mechanistic or biological studies are highlighted?
The FOA highlights immune profiling and genetic studies, as well as efforts to identify biomarkers that predict who is most likely to progress from normal glucose handling to impaired glucose tolerance and then to diabetes, including type 1 diabetes.
What does "harmonized data and biospecimens" mean in the context of this consortium?
In this program, harmonized data and biospecimens refer to information and samples collected using shared protocols and procedures across multiple sites, enabling pooled, cross-site analyses and more generalizable findings.
Why is enrolling a diverse cohort emphasized?
The FOA highlights the importance of enrolling a racially, ethnically, and geographically diverse cohort to support equity and to ensure that predictive biomarkers and risk models are valid in real-world populations rather than only in narrowly defined groups.
What does it mean that this is a consortium with common governance?
It means Clinical Centers are expected to operate as a true multi-site consortium with shared procedures, coordinated operations, and common governance, working closely with NIH and the DCC rather than functioning as fully independent projects.
Are clinical trials required for this opportunity?
No. The mechanism is described as U01 with "clinical trial optional," indicating that a clinical trial is not required based on the information provided.
Who is eligible to apply?
Eligibility is broad and includes many government entities (state, county, city/township, special districts), public and private institutions of higher education, tribal governments and organizations, nonprofits with or without 501(c)(3) status, public housing authorities/Indian housing authorities, for-profit organizations (other than small businesses), and small businesses. Additional eligibility details are referenced in the full announcement.
Does the opportunity support multi-site coordination across Clinical Centers?
Yes. The program is designed to be multi-site, with Clinical Centers coordinating closely with each other and with the DCC to implement shared protocols, consistent data collection, and consortium-wide operations.
What patient population is the consortium designed to follow?
The consortium focuses on people who experience acute pancreatitis and then develop impaired glucose tolerance or diabetes during the episode or in the months following the episode.
What is the overall goal of the consortium?
The overall goal is to build a coordinated clinical research network to understand diabetes that appears during or after acute pancreatitis, distinguish type 1 diabetes from other forms in this context, and improve diagnostic accuracy and earlier anticipation of treatment needs through longitudinal observation and mechanistic studies.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: Native Hawaiian Library Services Grant (2020)
Previous opportunity: Fiscal Year 2020 NMFS-Sea Grant Fellowship in Marine Resource Economics
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 19 022
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 19 022) also looked into and applied for these:
| Funding Opportunity |
|---|
| Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional) Apply for RFA DK 19 023 Funding Number: RFA DK 19 023 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed) Apply for RFA DK 20 006 Funding Number: RFA DK 20 006 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $130,000 |
| Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) Apply for PAR 20 140 Funding Number: PAR 20 140 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $200,000 |
| George M. O'Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional) Apply for RFA DK 20 008 Funding Number: RFA DK 20 008 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) Apply for RFA DK 20 024 Funding Number: RFA DK 20 024 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| NIDDK Research Education Program Utilizing Stimulating Peripheral Activity to Relieve Conditions (SPARC) - Generated Resources (R25 Clinical Trial Not Allowed) Apply for RFA DK 20 020 Funding Number: RFA DK 20 020 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $120,000 |
| Reconfiguration of GenitoUrinary Development Molecular Anatomy Project (GUDMAP) /(Re)Building A Kidney (RBK) Data Hub (U24 Clinical Trial Not Allowed) Apply for RFA DK 20 014 Funding Number: RFA DK 20 014 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $750,000 |
| Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required) Apply for RFA DK 20 032 Funding Number: RFA DK 20 032 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $225,000 |
| Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional) Apply for RFA HL 21 014 Funding Number: RFA HL 21 014 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Limited Competition: Revision to the Longitudinal Monitoring of Pancreas Architecture in the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional) Apply for RFA DK 21 501 Funding Number: RFA DK 21 501 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,500,000 |
| Standardization of C-Peptide and HbA1C Measurements Program (U01 Clinical Trial Not Allowed) Apply for RFA DK 21 007 Funding Number: RFA DK 21 007 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $350,000 |
| Advance conformance with the Voluntary National Retail Food Regulatory Program Standards (VNRFRPS) Apply for FOR FD 20 021 Funding Number: FOR FD 20 021 Agency: Department of Health and Human Services, Food and Drug Administration Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Manufactured Food Regulatory Program Alliance Apply for FOR FD 20 020 Funding Number: FOR FD 20 020 Agency: Department of Health and Human Services, Food and Drug Administration Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed) Apply for PAR 23 072 Funding Number: PAR 23 072 Agency: Department of Health and Human Services, Food and Drug Administration Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Enhancing Local Achievements in Nutrition Excellence (ELAINE) Apply for 7200AA23RFA00008 Funding Number: 7200AA23RFA00008 Agency: Agency for International Development Category: Food and Nutrition, Health Funding Amount: $99,500,000 |
| Produce Prescription Pilot Program Apply for HHS 2023 IHS PPPP 0001 Funding Number: HHS 2023 IHS PPPP 0001 Agency: Department of Health and Human Services, Indian Health Service Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Egg Safety Regulatory Program Standards Development (U18) Apply for RFA FD 16 040 Funding Number: RFA FD 16 040 Agency: Food and Drug Administration Category: Food and Nutrition, Health Funding Amount: $150,000 |
| Limited Competition: Understanding How Epigenetics and Infections Impact Autoimmunity and Diabetes in The Environmental Determinants of Diabetes In The Young Study (TEDDY) (UC4) Apply for RFA DK 15 506 Funding Number: RFA DK 15 506 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $22,000,000 |
| Diabetes Research Centers (P30) Apply for RFA DK 15 026 Funding Number: RFA DK 15 026 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK (R01) Apply for PA 16 374 Funding Number: PA 16 374 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 19 022", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.